Alvotech (ALVO) - Net Assets
Based on the latest financial reports, Alvotech (ALVO) has net assets worth Ikr-176.76 Million ISK (≈ $-1.44 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Ikr1.41 Billion ≈ $11.49 Million USD) and total liabilities (Ikr1.59 Billion ≈ $12.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check cash flow quality index of Alvotech to evaluate the quality of earnings relative to operating cash generation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Ikr-176.76 Million |
| % of Total Assets | -12.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Alvotech - Net Assets Trend (2020–2024)
This chart illustrates how Alvotech's net assets have evolved over time, based on quarterly financial data. See Alvotech (ALVO) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Alvotech (2020–2024)
The table below shows the annual net assets of Alvotech from 2020 to 2024. For live valuation and market cap data, see ALVO company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Ikr-412.77 Million ≈ $-3.37 Million |
+55.73% |
| 2023-12-31 | Ikr-932.49 Million ≈ $-7.60 Million |
-65.21% |
| 2022-12-31 | Ikr-564.42 Million ≈ $-4.60 Million |
-316.20% |
| 2021-12-31 | Ikr-135.61 Million ≈ $-1.11 Million |
+84.36% |
| 2020-12-31 | Ikr-867.24 Million ≈ $-7.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Alvotech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 139867900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Ikr2.02 Billion | % |
| Total Equity | Ikr-412.77 Million | 100.00% |
Alvotech Competitors by Market Cap
The table below lists competitors of Alvotech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SKAN Group AG
SW:SKAN
|
$1.07 Billion |
|
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
|
$1.10 Billion |
|
SUPERLOOP LTD
F:9SL
|
$1.07 Billion |
|
Dominos PIZZA Enterprises Ltd
AU:DMP
|
$1.06 Billion |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
$1.07 Billion |
|
Canaccord Genuity Group Inc
TO:CF
|
$1.08 Billion |
|
Jiangsu Wuyang Parking Industry Group Co Ltd
SHE:300420
|
$1.03 Billion |
|
Banco Patagonia
BA:BPAT
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alvotech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -932,493,000 to -412,771,000, a change of 519,722,000.
- Net loss of 231,864,000 reduced equity.
- New share issuances of 150,451,000 increased equity.
- Other factors increased equity by 601,135,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Ikr-231.86 Million | -56.17% |
| Share Issuances | Ikr150.45 Million | +36.45% |
| Other Changes | Ikr601.13 Million | +145.63% |
| Total Change | Ikr- | % |
Book Value vs Market Value Analysis
This analysis compares Alvotech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Ikr-3.56 | Ikr421.00 | x |
| 2021-12-31 | Ikr-0.56 | Ikr421.00 | x |
| 2022-12-31 | Ikr-2.27 | Ikr421.00 | x |
| 2023-12-31 | Ikr-3.49 | Ikr421.00 | x |
| 2024-12-31 | Ikr-1.37 | Ikr421.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alvotech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -47.35%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -255.26% | 0.14x | 0.00x | Ikr-83.32 Million |
| 2021 | 0.00% | -276.04% | 0.06x | 0.00x | Ikr-87.94 Million |
| 2022 | 0.00% | -618.55% | 0.10x | 0.00x | Ikr-457.14 Million |
| 2023 | 0.00% | -603.42% | 0.10x | 0.00x | Ikr-458.48 Million |
| 2024 | 0.00% | -47.35% | 0.40x | 0.00x | Ikr-190.59 Million |
Industry Comparison
This section compares Alvotech's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
No peer company data available for comparison.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more